Treatment MarketThe global castration-resistant prostate cancer (CRPC) treatment market is poised for substantial growth, ...

Astellas' first-in-class CLDN18.2 drug Vyloy has cleared the FDA. After a positive phase 3 readout, Otsuka is targeting an ...

Updated guidance from health technology assessment (HTA) agency NICE has concluded that Boston Scientific's HeartLogic and ...

This content was published on Oct 24, 2024 On Thursday, the Swiss Federal Railways presented its first fully renovated InterCity tilting train (ICN). Read more: Swiss railways presents first fully ...

DelveInsight's Protein Chip Market Insights report provides the current and forecast market analysis, individual leading protein ...

The FDA has approved a new drug called zolbetuximab designed to attack a novel target that’s in a type of stomach cancer.

Roche will use Dyno’s technology, through which Dyno applies AI and high-throughput in vivo data collection to engineering ...

George Church-founded Dyno Therapeutics Inc. is adding to its list of pharma deals by signing a second research collaboration ...

The global ulcerated necrobiosis lipoidica management market is poised for significant growth, with an anticipated valuation ...

Roche Holding AG is willing to pay more than $1 billion to solve one of the biggest challenges of gene therapy: delivery.

The U.S. Food and Drug Administration has approved Vyloy (zolbetuximab-clzb) in combination with fluoropyrimidine- and ...

The FDA has simultaneously granted approval to Astellas’ cancer drug Vyloy and to a companion diagnostic test developed by ...